NAARDEN, the Netherlands and MIAMI, Oct. 23, 2023 (GLOBE NEWSWIRE) NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Ian Somaiya as Chief Finan
Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid , respectively, indicating potential improvement of cholesterol metabolism in the brain Observed 8%.
NAARDEN, The Netherlands and MIAMI, Aug. 14, 2023 NewAmsterdam Pharma Company N.V. , a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of. -Today at 04:02 pm- MarketScreener